Diagnostic Value of Apolipoprotein C-I, Transthyretin and Apolipoprotein C-III in Gastric Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Mar 15

PMID 30867753

Citations 9

Authors

Min Wang

Jing Wang

Honggang Jiang

Affiliations

Soon will be listed here.

Abstract

Diagnostic value of apolipoprotein C-I (ApoC-I), transthyretin (TTR) and ApoC-III in gastric cancer were evaluated. Retrospective analysis methods were used to collect 60 patients with gastric cancer first diagnosed in The First Affiliated Hospital of Jiaxing University. There were 60 patients with chronic atrophic gastritis in the benign lesion group and 60 healthy individuals in the control group. The expression levels of serum ApoC-I, TTR and ApoC-III was detected by enzyme-linked immunosorbent assay. Differences existed in the expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group, benign lesion group and control group (P<0.001), with the expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group being lower than that of the benign lesion group (P<0.05), and the expression levels of ApoC-I, TTR and ApoC-III in the benign lesion group being lower than that of the control group (P<0.05). The expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group were to a certain degree correlated with the clinical stage, lymph node metastasis and differentiation of patients in the gastric cancer group (P<0.05). The specificity and negative predictive value of combined detection were proven to be higher than the separate detection of the three factors (P<0.05). The detection of serum ApoC-I, TTR and ApoC-III was of great significance in the diagnosis of gastric cancer and the estimation of its severity. The method of combined detection is worth a further in-depth study as it could improve the specificity of diagnosis and have a higher negative predictive value.

Citing Articles

Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.

Zhang A, Sun T, Yu D, Fu R, Liu X, Xue F Clin Exp Med. 2024; 24(1):154.

PMID: 38972952 PMC: 11228008. DOI: 10.1007/s10238-024-01350-y.

The Role of Apolipoproteins in the Commonest Cancers: A Review.

Darwish N, Al-Hail M, Mohamed Y, Al Saady R, Mohsen S, Zar A Cancers (Basel). 2023; 15(23).

PMID: 38067270 PMC: 10705282. DOI: 10.3390/cancers15235565.

Apolipoproteins: New players in cancers.

He Y, Chen J, Ma Y, Chen H Front Pharmacol. 2022; 13:1051280.

PMID: 36506554 PMC: 9732396. DOI: 10.3389/fphar.2022.1051280.

Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.

Naryzhny S, Ronzhina N, Zorina E, Kabachenko F, Klopov N, Zgoda V Int J Mol Sci. 2022; 23(19).

PMID: 36232415 PMC: 9569744. DOI: 10.3390/ijms231911113.

Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.

Hilbert M, Kuzman P, Mueller W, Meixensberger J, Nestler U Sci Rep. 2022; 12(1):16981.

PMID: 36216850 PMC: 9550816. DOI: 10.1038/s41598-022-21216-1.

References

Shachter N . Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001; 12(3):297-304. DOI: 10.1097/00041433-200106000-00009. View

Yanai H, Matsubara Y, Kawano T, Okamoto T, Hirano A, Nakamura Y . Clinical impact of strip biopsy for early gastric cancer. Gastrointest Endosc. 2004; 60(5):771-7. DOI: 10.1016/s0016-5107(04)02196-0. View

Kim T, Chung H, Yu W, Kim J, Kim G, Choi J . Localization of gastric cancer by CT gastrography: a prospective study. Hepatogastroenterology. 2009; 56(94-95):1580-4. View

Helgason H, Engwegen J, Zapatka M, Vincent A, Cats A, Boot H . Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncol Rep. 2010; 24(1):57-64. DOI: 10.3892/or_00000828. View

Fentz A, Sporl M, Spangenberg J, List H, Zornig C, Dorner A . Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels. Proteomics Clin Appl. 2010; 1(6):536-44. DOI: 10.1002/prca.200600664. View

Cohen M, Yossef R, Erez T, Kugel A, Welt M, Karpasas M . Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One. 2011; 6(1):e14540. PMC: 3022591. DOI: 10.1371/journal.pone.0014540. View

Ahn H, Shin Y, Park P, Kang K, Kim Y, Lee H . Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer. 2012; 106(4):733-9. PMC: 3322950. DOI: 10.1038/bjc.2011.592. View

Kang J, Chung H, Jeung H, Kim S, An S, Namkoong K . FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. Psychoneuroendocrinology. 2012; 37(9):1569-76. DOI: 10.1016/j.psyneuen.2012.02.017. View

Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y . Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2013; 17(1):26-33. DOI: 10.1007/s10120-013-0259-5. View

10.

Duffy M, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L . Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2013; 134(11):2513-22. PMC: 4217376. DOI: 10.1002/ijc.28384. View

11.

Rahman R, Asombang A, Ibdah J . Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014; 20(16):4483-90. PMC: 4000485. DOI: 10.3748/wjg.v20.i16.4483. View

12.

Choi J, Kim S, Im J, Kim J, Jung H . Long-term clinical outcomes of endoscopic resection for early gastric cancer. Surg Endosc. 2014; 29(5):1223-30. DOI: 10.1007/s00464-014-3800-7. View

13.

Vieira M, Saraiva M . Transthyretin: a multifaceted protein. Biomol Concepts. 2014; 5(1):45-54. DOI: 10.1515/bmc-2013-0038. View

14.

Yoon H, Kim N . Diagnosis and management of high risk group for gastric cancer. Gut Liver. 2014; 9(1):5-17. PMC: 4282848. DOI: 10.5009/gnl14118. View

15.

Takatsu Y, Hiki N, Nunobe S, Ohashi M, Honda M, Yamaguchi T . Clinicopathological features of gastric cancer in young patients. Gastric Cancer. 2015; 19(2):472-478. DOI: 10.1007/s10120-015-0484-1. View

16.

Jin Z, Jiang W, Wang L . Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). Oncol Lett. 2015; 9(4):1502-1508. PMC: 4356326. DOI: 10.3892/ol.2015.2959. View

17.

Kanda M, Kodera Y . Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015; 21(34):9838-52. PMC: 4566379. DOI: 10.3748/wjg.v21.i34.9838. View

18.

Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, Gholami G, Mehdizadeh J . The Valuable Role of Measuring Serum Lipid Profile in Cancer Progression. Oman Med J. 2015; 30(5):353-7. PMC: 4576393. DOI: 10.5001/omj.2015.71. View

19.

Huang Y, Yu J, Kang W, Ma Z, Ye X, Tian S . Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(11):e0142080. PMC: 4640555. DOI: 10.1371/journal.pone.0142080. View

20.

Wang C, Zhang J, Cai M, Zhu Z, Gu W, Yu Y . DBGC: A Database of Human Gastric Cancer. PLoS One. 2015; 10(11):e0142591. PMC: 4643992. DOI: 10.1371/journal.pone.0142591. View